UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Journal of clinical oncology, 2017-07, Vol.35 (19), p.2117-2124

2017

Volltextzugriff (PDF)

Androgen receptor-independent prostate cancer: an emerging clinical entity

Cancer biology & therapy, 2018-05, Vol.19 (5), p.347-348

2018

Volltextzugriff (PDF)

Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2

Modern pathology, 2024-03, Vol.37 (3), p.100424-100424, Article 100424

2024

Volltextzugriff (PDF)

Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management

Urologic oncology, 2024-05, Vol.42 (5), p.144-154

2024

Volltextzugriff (PDF)

443 Pembrolizumab for BCG refractory non-muscle invasive bladder cancer yields poor recurrence-free survival and high toxicity in patients

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A492-A492

2023

Volltextzugriff (PDF)

Are we training our fellows adequately in delivering bad news to patients? A survey of hematology/oncology program directors

Journal of palliative medicine, 2009-12, Vol.12 (12), p.1119

2009

Volltextzugriff (PDF)

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

The lancet oncology, 2021-07, Vol.22 (7), p.931-945

2021

Volltextzugriff (PDF)

Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL

Cancer chemotherapy and pharmacology, 2011-10, Vol.68 (4), p.1075-1080

2011

Volltextzugriff (PDF)

Where’s my doctor? the impact of the primary oncologist’s visit with their hospitalized patients

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.6603-6603

2019

Volltextzugriff (PDF)

Germline mutational profile in metastatic urothelial malignancy

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.550-550

2023

Volltextzugriff (PDF)

Androgen receptor inhibitors and anti-NKG2A checkpoint inhibitor to enhance NK cell–mediated killing of prostate cancer cell lines in vitro

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17066-e17066

2023

Volltextzugriff (PDF)

Lack of bleeding in patients with severe factor VII deficiency

American journal of hematology, 2005-02, Vol.78 (2), p.134-137

2005

Volltextzugriff (PDF)

BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.128-128

2022

Volltextzugriff (PDF)

Where's My Doctor? The Impact of the Primary Oncologist's Visit with Their Hospitalized Patients

Rhode Island medical journal (2013), 2023-02, Vol.106 (1), p.39-41

2023

Volltextzugriff (PDF)

Abstract 2195: Differential transcriptomic profiling of primary tumors and metastatic sites in advanced prostate cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2195-2195

2021

Volltextzugriff (PDF)

Abstract 1205: Clinical and genomic features of advanced urothelial carcinoma with 9p21 deletion

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1205-1205

2021

Volltextzugriff (PDF)

Declining Cancer Rates, Inclining Local Expertise: We Are Pointed in the Right Direction but Work Remains

Rhode Island medical journal (2013), 2020-04, Vol.103 (3), p.18-19

2020

Volltextzugriff (PDF)

Upper tract urothelial carcinoma with isolated lymph node involvement following surgical resection: Implications for multi-modal management

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16594-e16594

2018

Volltextzugriff (PDF)

KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.126-126

2020

Volltextzugriff (PDF)

Strategies to embed palliative care into a culture of cancer care

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e21678-e21678

2017

Volltextzugriff (PDF)

Why does Rhode Island have the greatest incidence of bladder cancer in the United States?

Medicine and health, Rhode Island, 2010-10, Vol.93 (10), p.308, 313

2010

Volltextzugriff (PDF)

KEYNOTE-046: ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5019-5019

2018

Volltextzugriff (PDF)

Genomic and immunologic profiles of concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4571-4571

2022

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(53)

Sprache

Englisch
(53)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(16)
Humans
(15)
Male
(9)
Oncology
(7)
Female
(6)
Middle Aged
(6)
Aged
(5)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Metastases
(4)
Metastasis
(4)
Patients
(4)
Adult
(3)
Aged, 80 And Over
(3)
Bladder Cancer
(3)
Hematologic And Hematopoietic Diseases
(3)
Immunotherapy
(3)
Prostate Cancer
(3)
Sepsis
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study

Androgen receptor-independent prostate cancer: an emerging clinical entity

Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2

Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management

443 Pembrolizumab for BCG refractory non-muscle invasive bladder cancer yields poor recurrence-free survival and high toxicity in patients

Are we training our fellows adequately in delivering bad news to patients? A survey of hematology/oncology program directors

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL

Where’s my doctor? the impact of the primary oncologist’s visit with their hospitalized patients

Germline mutational profile in metastatic urothelial malignancy

Androgen receptor inhibitors and anti-NKG2A checkpoint inhibitor to enhance NK cell–mediated killing of prostate cancer cell lines in vitro

Lack of bleeding in patients with severe factor VII deficiency

BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Where's My Doctor? The Impact of the Primary Oncologist's Visit with Their Hospitalized Patients

Abstract 2195: Differential transcriptomic profiling of primary tumors and metastatic sites in advanced prostate cancer

Abstract 1205: Clinical and genomic features of advanced urothelial carcinoma with 9p21 deletion

Declining Cancer Rates, Inclining Local Expertise: We Are Pointed in the Right Direction but Work Remains

Upper tract urothelial carcinoma with isolated lymph node involvement following surgical resection: Implications for multi-modal management

KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel

Strategies to embed palliative care into a culture of cancer care

Why does Rhode Island have the greatest incidence of bladder cancer in the United States?

KEYNOTE-046: ADXS-PSA plus pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC)

Genomic and immunologic profiles of concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer

Suchergebnisse filtern